More Than 100 Years of Exceptional Service & Care
For more than a century, Montefiore Einstein Medical Oncology has been at the forefront of cancer treatment research and education. As part of the Montefiore Einstein Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center, we are among the elite 1% of U.S. hospitals recognized for excellence in cancer care.
Our team of doctors has unparalleled expertise in cancer care, using a research-based and personalized approach tailored to the unique needs of each patient. We employ the latest and most advanced diagnostics and treatments available, including next-generation genomic sequencing and the most up-to-date Food and Drug Administration (FDA)-approved and newly emerging targeted therapies to eliminate or control cancer, manage symptoms, prevent recurrence, and improve the health and quality of life for each patient.
We have a long history of making paradigm-shifting contributions to basic, translational and clinical research, as well as seminal discoveries, many of which have been published in high-impact journals. We paved the way for FDA approval of luspatercept-aamt (REBLOZYL®) to treat myelodysplastic syndrome (MDS)-related anemia—the first new treatment option for MDS in more than a decade. We also identified potential biomarkers for pinpointing the subset of individuals with estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have an increased risk for developing metastatic disease. We continue to establish new standards of care in oncology and have been involved in multiple trials that have led to FDA approval of novel medications.
